The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Endometrial cancer (EC) by ERBB2 amplification (ERBB2amp) status: Differences in molecular subtypes, ancestry, and real-world outcomes.
 
Thomas J. Herzog
Leadership - GOG Foundation
Consulting or Advisory Role - Aadi; AstraZeneca; Caris MPI; Clovis Oncology; Corcept Therapeutics; Eisai; Epsilogen; GlaxoSmithKline; Johnson & Johnson; Merck; Mersana; Seagen
 
Natalie Danziger
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Douglas I. Lin
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche Pharma AG
 
Julia A. Elvin
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Andrew David Kelly
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Foundation Medicine
 
Ryon P Graf
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Epic Sciences; Foundation Medicine
 
Robert L. Coleman
Employment - US Oncology; Vaniam Group
Leadership - Onxeo
Stock and Other Ownership Interests - McKesson/US Oncology Network
Consulting or Advisory Role - Abbvie; Agenus; Alkermes; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; GOG Foundation; Gradalis; Immunogen; Karyopharm Therapeutics; Merck; Merck; Novocure; OncoMed; OncXerna Therapeutics
Research Funding - Alkermes; Amgen (Inst); AstraZeneca/MedImmune; Clovis Oncology (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck; Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (I)
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group
 
Bhavana Pothuri
Honoraria - Bio Ascend; OncLive; PER; Projects in Knowledge; YALE UNIVERSITY
Consulting or Advisory Role - AstraZeneca; Celsion; Curio Science; Eisai; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; Incyte; Incyte; InxMed; Lilly; Merck; Mersana; Onconova Therapeutics; Peerview; R-Pharm; Regeneron; Seagen; Signatera; Sutro Biopharma; WebMD
Research Funding - Acrivon Therapeutics (Inst); Agenus (Inst); AstraZeneca (Inst); Celgene (Inst); Celsion (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); InxMed (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mersana (Inst); Novocure (Inst); NRG Oncology (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Sutro Biopharma (Inst); Takeda (Inst); Tesaro (Inst); Toray Industries (Inst); VBL Therapeutics (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - GOG Foundation; Merck; Seagen
Other Relationship - Society of Gynecologic Oncology
 
Ramez Nassef Eskander
Consulting or Advisory Role - AstraZeneca/MedImmune; BioNTech SE; Daiichi Sankyo/Lilly; Eisai; Gilead Sciences; GlaxoSmithKline; Immunogen; Merck; Myriad Genetics; PMV Pharma; Regeneron; Seagen
Speakers' Bureau - AstraZeneca/MedImmune
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Eisai; Merck
Other Relationship - GOG Foundation; The Clearity Foundation
 
Julia Quintanilha
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - United States Patent: "Methods of identifying risk of bevacizumab-induced proteinuria and hypertension", Innocenti F., Quintanilha J., Lin D., Owzar K., Wang J. Filed on July 17, 2020, serial number 16/932002; United States Provisional Patent Application: "Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab induced hypertension", Innocenti F., Quintanilha J. Filed on April 1, 2021, serial number 63/169301
Travel, Accommodations, Expenses - Foundation Medicine
 
Brian M. Slomovitz
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Eisai; EQRx; Genentech; Genmab; Gilead Sciences; GlaxoSmithKline; GOG Foundation; Lilly; Merck; Nuvation Bio; Onconova Therapeutics; Onconova Therapeutics; Regeneron; Seagen